Concepts (139)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Models, Statistical | 4 | 2019 | 180 | 1.480 |
Why?
|
| Probability | 3 | 2019 | 78 | 1.380 |
Why?
|
| Computer Simulation | 3 | 2022 | 362 | 0.910 |
Why?
|
| Research Design | 2 | 2022 | 313 | 0.840 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 268 | 0.800 |
Why?
|
| Malaria, Falciparum | 2 | 2022 | 90 | 0.750 |
Why?
|
| Medicaid | 2 | 2018 | 109 | 0.720 |
Why?
|
| Treatment Outcome | 3 | 2019 | 1369 | 0.720 |
Why?
|
| HIV Infections | 7 | 2023 | 2303 | 0.710 |
Why?
|
| Survival Analysis | 2 | 2018 | 325 | 0.710 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 108 | 0.690 |
Why?
|
| Antigens, Protozoan | 2 | 2022 | 72 | 0.630 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 204 | 0.630 |
Why?
|
| Antibodies, Protozoan | 2 | 2022 | 79 | 0.630 |
Why?
|
| Antiviral Agents | 1 | 2019 | 157 | 0.630 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 2017 | 12 | 0.610 |
Why?
|
| Myocardial Ischemia | 1 | 2018 | 75 | 0.600 |
Why?
|
| Plasmodium falciparum | 2 | 2022 | 135 | 0.590 |
Why?
|
| Placenta | 1 | 2017 | 97 | 0.580 |
Why?
|
| Prognosis | 1 | 2019 | 739 | 0.550 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 106 | 0.550 |
Why?
|
| Disease Progression | 1 | 2018 | 601 | 0.530 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 306 | 0.530 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 169 | 0.520 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 276 | 0.510 |
Why?
|
| Huntington Disease | 3 | 2024 | 27 | 0.480 |
Why?
|
| Gene Expression | 1 | 2016 | 674 | 0.460 |
Why?
|
| Humans | 27 | 2024 | 37093 | 0.460 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 485 | 0.430 |
Why?
|
| Hawaii | 8 | 2023 | 1929 | 0.390 |
Why?
|
| Neurodegenerative Diseases | 2 | 2024 | 131 | 0.390 |
Why?
|
| Censuses | 2 | 2023 | 24 | 0.290 |
Why?
|
| Regression Analysis | 2 | 2017 | 455 | 0.280 |
Why?
|
| Health Status Disparities | 2 | 2023 | 642 | 0.270 |
Why?
|
| Anti-HIV Agents | 2 | 2020 | 420 | 0.260 |
Why?
|
| Retrospective Studies | 3 | 2023 | 2026 | 0.240 |
Why?
|
| Male | 10 | 2023 | 20025 | 0.240 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 664 | 0.240 |
Why?
|
| Female | 10 | 2023 | 20969 | 0.230 |
Why?
|
| Aged | 4 | 2020 | 6741 | 0.230 |
Why?
|
| Age Distribution | 1 | 2023 | 225 | 0.220 |
Why?
|
| Sex Distribution | 1 | 2023 | 215 | 0.220 |
Why?
|
| United States | 4 | 2023 | 4223 | 0.200 |
Why?
|
| Malaria | 1 | 2022 | 78 | 0.200 |
Why?
|
| Middle Aged | 7 | 2020 | 10129 | 0.200 |
Why?
|
| Family Practice | 1 | 2022 | 49 | 0.200 |
Why?
|
| Atherosclerosis | 1 | 2023 | 134 | 0.200 |
Why?
|
| Peptides | 1 | 2024 | 320 | 0.190 |
Why?
|
| Mitochondrial Membranes | 1 | 2021 | 40 | 0.190 |
Why?
|
| Carotid Stenosis | 1 | 2020 | 13 | 0.190 |
Why?
|
| Internship and Residency | 1 | 2022 | 125 | 0.190 |
Why?
|
| Carotid Artery Diseases | 1 | 2020 | 22 | 0.190 |
Why?
|
| Hepatitis C | 1 | 2022 | 125 | 0.190 |
Why?
|
| Oxidative Phosphorylation | 1 | 2020 | 53 | 0.180 |
Why?
|
| Biostatistics | 1 | 2019 | 7 | 0.180 |
Why?
|
| Double-Blind Method | 1 | 2019 | 286 | 0.170 |
Why?
|
| Receptors, Immunologic | 1 | 2019 | 61 | 0.170 |
Why?
|
| Adult | 6 | 2022 | 11712 | 0.170 |
Why?
|
| Infant | 2 | 2022 | 1046 | 0.160 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 113 | 0.160 |
Why?
|
| Coronary Vessels | 1 | 2019 | 85 | 0.160 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2020 | 234 | 0.160 |
Why?
|
| Endocrine System Diseases | 1 | 2018 | 13 | 0.160 |
Why?
|
| Insurance Claim Review | 1 | 2018 | 28 | 0.160 |
Why?
|
| Blood-Brain Barrier | 1 | 2019 | 162 | 0.160 |
Why?
|
| Empirical Research | 1 | 2017 | 5 | 0.160 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 583 | 0.150 |
Why?
|
| Metabolic Diseases | 1 | 2018 | 33 | 0.150 |
Why?
|
| Cameroon | 1 | 2017 | 38 | 0.150 |
Why?
|
| Bone Marrow Transplantation | 1 | 2017 | 15 | 0.150 |
Why?
|
| Markov Chains | 1 | 2017 | 35 | 0.150 |
Why?
|
| Communicable Diseases | 1 | 2018 | 45 | 0.150 |
Why?
|
| Linear Models | 1 | 2018 | 275 | 0.150 |
Why?
|
| Lung Diseases | 1 | 2018 | 61 | 0.150 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 259 | 0.150 |
Why?
|
| Leukemia | 1 | 2017 | 56 | 0.150 |
Why?
|
| Risk Factors | 3 | 2023 | 3562 | 0.150 |
Why?
|
| Mental Health Services | 1 | 2018 | 118 | 0.150 |
Why?
|
| Spinal Cord Injuries | 1 | 2017 | 56 | 0.150 |
Why?
|
| Neuroprotective Agents | 1 | 2019 | 245 | 0.140 |
Why?
|
| Adolescent | 2 | 2018 | 5363 | 0.140 |
Why?
|
| Medicare | 1 | 2018 | 195 | 0.140 |
Why?
|
| Quality of Life | 1 | 2020 | 481 | 0.140 |
Why?
|
| Mutation | 1 | 2021 | 1095 | 0.140 |
Why?
|
| Mitochondria | 1 | 2020 | 487 | 0.140 |
Why?
|
| Comorbidity | 1 | 2018 | 623 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2018 | 484 | 0.130 |
Why?
|
| Monocytes | 3 | 2023 | 257 | 0.120 |
Why?
|
| RNA | 1 | 2016 | 241 | 0.120 |
Why?
|
| HIV-1 | 1 | 2020 | 706 | 0.120 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 1067 | 0.120 |
Why?
|
| Child, Preschool | 1 | 2018 | 1418 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2019 | 426 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 807 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 494 | 0.110 |
Why?
|
| Pregnancy | 1 | 2017 | 1549 | 0.100 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 2379 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2016 | 1618 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 643 | 0.100 |
Why?
|
| Young Adult | 2 | 2018 | 4268 | 0.090 |
Why?
|
| Child | 1 | 2018 | 3131 | 0.090 |
Why?
|
| Rats | 1 | 2016 | 3483 | 0.080 |
Why?
|
| Cross-Sectional Studies | 3 | 2020 | 2721 | 0.080 |
Why?
|
| Animals | 2 | 2024 | 15081 | 0.060 |
Why?
|
| Amyloid | 1 | 2024 | 54 | 0.060 |
Why?
|
| Cyclohexanes | 1 | 2023 | 30 | 0.060 |
Why?
|
| Guam | 1 | 2023 | 79 | 0.060 |
Why?
|
| Caenorhabditis elegans | 1 | 2024 | 78 | 0.060 |
Why?
|
| Vascular Surgical Procedures | 1 | 2023 | 14 | 0.060 |
Why?
|
| Translating | 1 | 2023 | 16 | 0.060 |
Why?
|
| Antibody Formation | 1 | 2022 | 74 | 0.050 |
Why?
|
| Merozoite Surface Protein 1 | 1 | 2022 | 35 | 0.050 |
Why?
|
| Triazoles | 1 | 2023 | 86 | 0.050 |
Why?
|
| Communication Barriers | 1 | 2023 | 56 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2022 | 82 | 0.050 |
Why?
|
| Lipids | 1 | 2024 | 235 | 0.050 |
Why?
|
| Neopterin | 1 | 2022 | 13 | 0.050 |
Why?
|
| HLA-DR Antigens | 1 | 2022 | 21 | 0.050 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2023 | 221 | 0.050 |
Why?
|
| Vietnam | 1 | 2022 | 50 | 0.050 |
Why?
|
| Cyclopropanes | 1 | 2022 | 40 | 0.050 |
Why?
|
| Alkynes | 1 | 2022 | 50 | 0.050 |
Why?
|
| Benzoxazines | 1 | 2022 | 46 | 0.050 |
Why?
|
| Hepacivirus | 1 | 2022 | 62 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2023 | 210 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 237 | 0.050 |
Why?
|
| Faculty | 1 | 2022 | 94 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2020 | 56 | 0.050 |
Why?
|
| Lipid Bilayers | 1 | 2021 | 68 | 0.050 |
Why?
|
| CD4-CD8 Ratio | 1 | 2020 | 30 | 0.050 |
Why?
|
| Glutathione | 1 | 2021 | 179 | 0.050 |
Why?
|
| Curriculum | 1 | 2022 | 265 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2020 | 236 | 0.040 |
Why?
|
| Prevalence | 1 | 2023 | 1455 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 186 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2020 | 301 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2021 | 453 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 610 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2019 | 142 | 0.040 |
Why?
|